Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Royalty Pharma PLC (RPRX : NSDQ)

• Company Description    Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK. Number of Employees: 99

• Price / Volume Information    Yesterday's Closing Price: $36.36 Daily Weekly Monthly 20 Day Moving Average: 3,744,514 shares Shares Outstanding: 583.17 (millions) Market Capitalization: $21,204.21 (millions) Beta: 0.58 52 Week High: $38.00 52 Week Low: $24.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.38% -2.13% 12 Week 4.15% -5.39% Year To Date 42.53% 28.45%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 110 East 59th Street - New York,NY 10022 USA ph: 212-883-0200 fax: - ir@royaltypharma.com http://www.royaltypharma.com

• General Corporate Information    Officers Pablo Legorreta - Chairman of the Board; Director & Chief Executive Terrance Coyne - Executive Vice President & Chief Financial Officer Bonnie Bassler - Director Errol De Souza - Director Catherine Engelbert - Director Peer Information Royalty Pharma PLC (CORR.) Royalty Pharma PLC (RSPI) Royalty Pharma PLC (CGXP) Royalty Pharma PLC (BGEN) Royalty Pharma PLC (GTBP) Royalty Pharma PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G7709Q104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 583.17 Most Recent Split Date: (:1) Beta: 0.58 Market Capitalization: $21,204.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 2.42% Current Fiscal Quarter EPS Consensus Estimate: $1.10 Indicated Annual Dividend: $0.88 Current Fiscal Year EPS Consensus Estimate: $4.56 Payout Ratio: 0.20 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: -0.03 Estmated Long-Term EPS Growth Rate: 3.51% Last Dividend Paid: 08/15/2025 - $0.22 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: 7.97 Trailing 12 Months: 8.28 PEG Ratio: 2.27 Price Ratios Price/Book: 2.23 Price/Cash Flow: 8.67 Price / Sales: 9.20 EPS Growth vs. Year Ago Period: 18.75% vs. Previous Quarter: 7.55% Sales Growth vs. Year Ago Period: 7.82% vs. Previous Quarter: 1.94% ROE 06/30/25 - 25.54 03/31/25 - 24.71 12/31/24 - 24.40 ROA 06/30/25 - 14.11 03/31/25 - 13.87 12/31/24 - 14.01 Current Ratio 06/30/25 - 1.26 03/31/25 - 1.56 12/31/24 - 1.44 Quick Ratio 06/30/25 - 1.26 03/31/25 - 1.56 12/31/24 - 1.44 Operating Margin 06/30/25 - 110.45 03/31/25 - 109.54 12/31/24 - 108.35 Net Margin 06/30/25 - 44.23 03/31/25 - 48.23 12/31/24 - 37.94 Pre-Tax Margin 06/30/25 - 72.19 03/31/25 - 78.11 12/31/24 - 58.79 Book Value 06/30/25 - 16.30 03/31/25 - 17.28 12/31/24 - 17.56 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.74 03/31/25 - 0.68 12/31/24 - 0.64 Debt-to-Capital 06/30/25 - 42.43 03/31/25 - 40.34 12/31/24 - 39.01

Powered by Zacks Investment Research ©